Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma

Trial Profile

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPI-818 (Primary)
  • Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Corvus Pharmaceuticals
  • Most Recent Events

    • 30 Apr 2020 According to a Corvus Pharmaceuticals media release, updated data from this trial is planned to be presented at the American Society of Hematology (ASH) annual meeting in December 2020.
    • 30 Apr 2020 According to a Corvus Pharmaceuticals media release, enrollment in the dose escalation portion has been completed, optimum dose for CPI-818 has selected and began the next portion of the study with a focus on patients with cutaneous T-cell lymphoma.
    • 01 Feb 2020 According to a Corvus Pharmaceuticals media release, the company is now ready to advance the trial to higher drug doses where they will evaluate CPI-818 activity in specific disease cohorts.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top